Articles tagged with Cancer Medication
Researchers have developed a groundbreaking approach using specially designed peptides to improve drug formulations, significantly enhancing anti-tumor efficacy in leukemia models. The innovative method achieves high drug loadings and optimizes delivery to targeted areas, holding significant potential for treating various diseases.
A new study from the Salk Institute has discovered that a protein called BCL6 plays a crucial role in maintaining healthy muscle mass. Increasing BCL6 levels successfully reversed muscle losses in mice, suggesting that pairing GLP-1 medications with a BCL6-boosting drug could help counteract unwanted muscle loss.
Researchers explore HER2-low breast cancer, a new clinical subtype that benefits from novel treatments and personalized care. Current testing methods are not always accurate, calling for better detection methods to correctly identify patients who can benefit from these new therapies.
According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
Researchers discovered that the protein PIN1 drives bladder cancer by triggering cholesterol synthesis, which fuels out-of-control cell growth. A combination of statins and a PIN1 inhibitor effectively blocks tumor growth in mice, offering a promising therapeutic approach for this deadly disease.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
Researchers developed a computer model to predict which medication works best for each individual patient with CML. The approach has the potential to improve treatment outcomes for patients who previously relied on stem cell transplantation.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Researchers developed a novel inhalable therapeutic delivery system for lung cancer using mucoadhesive protein nanoparticles inspired by marine mussels. The approach leverages the adhesive properties of mussel proteins to enable selective payload release and minimize adverse effects.
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
Researchers developed biodegradable polymeric nanoparticles that selectively target cancer cells with two approved drug pairs for skin and breast cancers. The treatment showed significantly enhanced therapeutic effects, reduced tumor size, and prolonged median survival in mice.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
A new Northwestern Medicine study reveals how metformin lowers glucose levels by targeting mitochondrial complex I in cells. The drug also improves COVID outcomes and reduces inflammation, suggesting that mitochondrial complex I inhibition may be a unifying mechanism behind its diverse effects.
A new study explores whether CBD can reduce scan-related anxiety in advanced breast cancer patients, finding it was safe but did not significantly change anxiety levels. However, participants who consumed CBD experienced lower anxiety levels after treatment.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
A new review published in Blood Cancer Discovery outlines how research supported a recent FDA committee decision to allow minimal residual disease as an endpoint for accelerated approval in multiple myeloma. This decision could cut a decade off the drug development process, enabling faster innovation in cancer treatment.
Researchers have identified a promising new drug, lomonitinib, targeting treatment-resistant acute myeloid leukemia (AML) with FLT-3 mutation. Additionally, they developed a novel compound to target MALT1 protein in chronic lymphocytic leukemia (CLL), aiming to provide better control of the disease.
Researchers at Tokyo University of Science have developed a new, highly selective and efficient method for synthesizing anti-cancer compounds. The innovative approach uses isopropyl magnesium bromide as a base to improve selectivity and scalability.
New research from the University of Pittsburgh found that opioids can suppress the immune system and reduce the effectiveness of immunotherapy for head and neck cancer. However, peripherally restricted OPRM1 antagonists (PAMORAs) may block opioid-induced immunosuppression and improve response rates to immune checkpoint inhibitor therapy.
A new study has solved a years-old mystery about which patients with aggressive breast cancer are helped by a targeted cancer treatment. The researchers found that low levels of the protein IGFBP7 can predict which patients will benefit from the treatment, providing hope for its continued development.
A new framework developed by UCLA researchers suggests that genetic data from large libraries of sequenced human genomes can improve the predictive power of genetics in determining how well a patient will respond to commonly prescribed medications and the severity of any side effects. The study, which analyzed data from over 342,000 pe...
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
Combining PVA with a boron-containing compound improved the effects of radiation therapy for cancer, making it more selective of tumor cells and prolonging drug retention. This breakthrough could lead to more effective treatment options for challenging cancers.
Researchers found that certain cancer treatments, such as immune checkpoint inhibitors, can trigger damaging levels of inflammation in the heart and increase risk of heart disease. This is because these treatments interfere with immune regulation in the heart's largest blood vessels.
A new study has found that tamoxifen works better for some people due to their unique gut microbiota. Researchers discovered a specific enzyme, beta-glucuronidase, in certain bacteria that helps recycle the drug into its effective form. This finding may lead to tailored treatment interventions for breast cancer patients.
Researchers explore adapting agricultural techniques, such as integrated pest management, to treat cancer. By managing cancer as a chronic condition, adaptive therapy aims to overcome treatment resistance and improve patient outcomes.
The EMA's orphan designation for G2B-002 marks a significant milestone in the fight against pediatric brain tumors. The innovative product leverages Gate2Brain's proprietary technology to enhance drug delivery across the blood-brain barrier, promising enhanced effectiveness and safety for complex cancer treatments.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
A recent analysis reveals significant gaps in cancer drug cost and availability between high- and low-income countries. Inequities in access to therapy, screening, and healthcare infrastructure contribute to higher cancer incidence and mortality rates in low-income countries.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
Researchers at Uppsala University have developed a unique antibody that targets and delivers a drug package while activating the immune system. This '3-in-1 design' method has shown promise in treating several types of cancer by amplifying T cell effect on cancer tumors.
Researchers developed a 36-gene predictive score that surpasses conventional methods in predicting tamoxifen treatment resistance. The polygenic score UAB36 has potential as a tool for personalized medicine, helping identify patients at higher risk of poor survival and suggesting alternative treatment strategies.
A new study by MUSC researchers reveals how cancer cells develop resistance to hydroxychloroquine, an anti-malarial drug repurposed for cancer therapy. The findings suggest that targeting specific metabolic and export pathways can prevent resistance, opening the door for novel combination therapies.
A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.
A new anti-cancer agent has been developed that targets glutathione in cancer cells, switching it off and causing tumor shrinkage. The catalyst-based therapy accumulates specifically in tumor tissue, showing promising results in animal studies and potential for further human trials.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
Dr. Fyodor Urnav proposes a set of initiatives to address the crisis, including pooling patients by syndrome and permitting multiple gene editors in a single Investigational New Drug application. This approach aims to accelerate the development of CRISPR therapies for rare genetic diseases.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Polyploidy, a state with extra genetic material, allows cancer cells to survive longer under DNA damage. This phenomenon explains why some cancers are resistant to anti-cancer drug treatments.
A new study has identified four categories of cancer mutations that cause drug resistance, providing targets for drug development and potential effective second-line therapies. The research highlights DNA changes that could be explored further to treat patients with specific genetic mutations.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
Researchers found that the oral medication palbociclib stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis, a form of appendix cancer often resistant to standard chemotherapy. The study's findings introduce a first targeted therapy for this rare disease.
Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.
A global analysis of new cancer drug launches between 1990 and 2022 found significant disparities in availability and timeliness, with poorer countries missing out. The gap between rich and poor nations widened over three decades, suggesting such inequities may explain poor cancer outcomes in many lower-income countries.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Researchers at CNIO propose a new treatment for brain metastasis by targeting pro-tumour astrocytes with immunotherapy. They identified TIMP1 as a biomarker to predict when immunotherapy is effective, and a clinical trial is underway to test the therapeutic efficacy of silibinin inhibition.
Scientists at RIKEN CPR created a method to change albumin's molecular ID card, allowing for targeted treatments against diseases like cancer. The new technology can transport proteins out of the body, mimicking drug delivery and removal.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers discovered ponsegromab, a monoclonal antibody, improves symptoms of cachexia by blocking the GDF-15 hormone. The treatment shows minimal side effects and boosts weight gain and patient activity in cancer patients.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
Researchers found a significant reduction in nosebleed severity, fewer transfusions, and improved quality of life in patients with hereditary hemorrhagic telangiectasia treated with pomalidomide. The trial's results offer hope for people with this rare bleeding disorder.
Researchers at NYU Abu Dhabi have developed nanoscale covalent organic frameworks (nCOFs) modified with peptides to treat triple-negative breast cancer. The COFs selectively release drug cargo within the acidic environment of tumors, improving treatment effectiveness and minimizing side effects.